Edmund Paloyan, MD
Medical Oncology · Saint Joseph, MINPI 1972509081
Payments from drug & device makers
Across 137 payments — averaging $142.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$17K
- Genentech USA, Inc.$302
- Johnson & Johnson$225
- Novartis$198
- Foundation Medicine, Inc.$183
- Pfizer$148
- plus $1K from 32 others
What the payments were for
- Consulting fees$17,00087%
- Food & beverage$2,45113%
- Education$770%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 1 | $17,000 |
| Genentech USA, Inc. | 18 | $302 |
| Johnson & Johnson | 6 | $225 |
| Novartis | 11 | $198 |
| Foundation Medicine, Inc. | 3 | $183 |
| Pfizer | 13 | $148 |
| E.r. Squibb & Sons, L.L.C. | 7 | $139 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $108 |
| Bristol Myers Squibb | 5 | $98 |
| Gilead(2 entities) | 6 | $88 |
| Merck | 5 | $84 |
| AstraZeneca | 5 | $84 |
| Astellas Pharma US Inc | 4 | $81 |
| Eisai Inc. | 4 | $72 |
| Ipsen Biopharmaceuticals, Inc | 3 | $65 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $50 |
| Regeneron Healthcare Solutions, Inc. | 2 | $43 |
| Taiho Oncology, Inc. | 2 | $42 |
| Lilly USA, LLC | 3 | $42 |
| Tersera Therapeutics LLC | 3 | $40 |
| Amgen | 2 | $38 |
| Verastem, Inc. | 2 | $37 |
| Tesaro, Inc. | 2 | $35 |
| Seagen Inc. | 2 | $32 |
| Clovis Oncology, Inc. | 3 | $31 |
| Boehringer Ingelheim | 2 | $28 |
| AbbVie | 2 | $25 |
| Sanofi-aventis U.S. LLC | 1 | $25 |
| Sanofi | 2 | $24 |
| Stemline Therapeutics Inc. | 1 | $24 |
| Myovant Sciences Inc. | 1 | $24 |
| EMD Serono, Inc. | 1 | $20 |
| Pharmacosmos Therapeutics Inc. | 1 | $19 |
| Sobi, Inc | 1 | $17 |
| Verity Pharmaceuticals Inc. | 1 | $16 |
| EUSA Pharma (US) LLC | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $13 |
| Array Biopharma Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RXSIGHT CONTACT LENS$17,000
- RXSIGHT INJECTOR CARTRIDGE$17,000
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$17,000
- LIGHT ADJUSTABLE LENS (LAL)$17,000
- RXSIGHT INJECTOR HANDPIECE$17,000
- RYBREVANT$150
- CARVYKTI$150
- FOUNDATIONONE$147
- FOUNDATIONONE HEME$147
- FOUNDATIONONE CDX$147
- FOUNDATIONFOCUS$147
- FOUNDATIONONE LIQUID$147
How this compares
$19,529 in reported general payments places this provider in the 45th percentile of 170 medical oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 68 | $1,014,697 |
| PomalystPomalidomide | 36 | $881,658 |
| ErleadaApalutamide | 47 | $820,411 |
| VenclextaVenetoclax | 52 | $619,043 |
| PromactaEltrombopag Olamine | 25 | $471,706 |
| RevlimidLenalidomide | 20 | $340,868 |
| JakafiRuxolitinib Phosphate | 27 | $306,377 |
| CabometyxCabozantinib S-Malate | 11 | $301,577 |
| Lenalidomide | 22 | $241,180 |
| XtandiEnzalutamide | 23 | $227,652 |
| KisqaliRibociclib Succinate | 12 | $174,895 |
| BrukinsaZanubrutinib | 11 | $156,114 |
| EliquisApixaban | 192 | $137,216 |
| TasignaNilotinib Hcl | 12 | $126,334 |
| XareltoRivaroxaban | 88 | $73,155 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $148 | $1,151,913260 claims |
| Johnson & JohnsonErleada, Xarelto | $225 | $893,566135 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $139 | $881,65836 claims |
| NovartisPromacta, Kisqali, Tasigna | $198 | $772,93549 claims |
| AbbVieVenclexta | $25 | $619,04352 claims |
| Bristol Myers SquibbRevlimid | $98 | $340,86820 claims |
| Astellas Pharma US IncXtandi | $81 | $227,65223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 170 medical oncology providers in Michigan.
Other medical oncology in Saint Joseph
- Sapna PatelSaint Joseph$611K
- Patricia Lo RussoDetroit$24.6M
- Manish SharmaGrand Rapids$19M
- Moshe TalpazAnn Arbor$13.7M
- Shirish GadgeelDetroit$11M
- Zachery ReichertAnn Arbor$10.6M
- Ammar SukariDetroit$8.4M
- Paul SwiecickiAnn Arbor$7.6M
- Rashmi ChughAnn Arbor$7M
- John KraussAnn Arbor$6.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.